Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 166
Filtrar
1.
Ann R Coll Surg Engl ; 102(2): e26-e28, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31418283

RESUMEN

Superior mesenteric artery syndrome, a rare cause of duodenal obstruction, occasionally requires surgery. Bowel emphysema might also require surgery and might be an ominous sign of a serious condition. We report the case of a 69-year-old Japanese man with left pneumothorax who was also diagnosed as having bowel emphysema and superior mesenteric artery syndrome simultaneously without serious infection after surgery for the pneumothorax. Following gastric decompression via a nasogastric tube, his general condition resolved quickly with no need for surgical intervention. Prompt and precise diagnosis by computed tomography and both adequate judgment and treatment can avoid surgery in such cases.


Asunto(s)
Enfisema/etiología , Intubación Gastrointestinal , Enfisema Pulmonar/cirugía , Síndrome de la Arteria Mesentérica Superior/etiología , Cirugía Torácica Asistida por Video/efectos adversos , Anciano , Duodeno/diagnóstico por imagen , Enfisema/diagnóstico , Enfisema/terapia , Humanos , Pulmón/diagnóstico por imagen , Pulmón/cirugía , Masculino , Enfisema Pulmonar/complicaciones , Enfisema Pulmonar/diagnóstico por imagen , Síndrome de la Arteria Mesentérica Superior/diagnóstico , Síndrome de la Arteria Mesentérica Superior/terapia , Tomografía Computarizada por Rayos X , Resultado del Tratamiento
2.
Am J Transplant ; 16(8): 2334-41, 2016 08.
Artículo en Inglés | MEDLINE | ID: mdl-26833657

RESUMEN

We examined the effect of alemtuzumab and basiliximab induction therapy on patient survival and freedom from bronchiolitis obliterans syndrome (BOS) in double lung transplantation. The United Network for Organ Sharing database was reviewed for adult double lung transplant recipients from 2006 to 2013. The primary outcome was risk-adjusted all-cause mortality. Secondary outcomes included time to BOS. There were 6117 patients were identified, of whom 738 received alemtuzumab, 2804 received basiliximab, and 2575 received no induction. Alemtuzumab recipients had higher lung allocation scores compared with basiliximab and no-induction recipients (41.4 versus 37.9 versus 40.7, p < 0.001) and were more likely to require mechanical ventilation before to transplantation (21.7% versus 6.5% versus 6.2%, p < 0.001). Median survival was longer for alemtuzumab and basiliximab recipients compared with patients who received no induction (2321 versus 2352 versus 1967 days, p = 0.001). Alemtuzumab (hazard ratio 0.80, 95% confidence interval 0.67-0.95, p = 0.009) and basiliximab induction (0.88, 0.80-0.98, p = 0.015) were independently associated with survival on multivariate analysis. At 5 years, alemtuzumab recipients had a lower incidence of BOS (22.7% versus 55.4 versus 55.9%), and its use was independently associated with lower risk of developing BOS on multivariate analysis. While both induction therapies were associated with improved survival, patients who received alemtuzumab had greater median freedom from BOS.


Asunto(s)
Alemtuzumab/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Bronquiolitis Obliterante/mortalidad , Rechazo de Injerto/mortalidad , Enfermedades Pulmonares/mortalidad , Trasplante de Pulmón/efectos adversos , Proteínas Recombinantes de Fusión/uso terapéutico , Adulto , Antineoplásicos/uso terapéutico , Basiliximab , Bronquiolitis Obliterante/tratamiento farmacológico , Bronquiolitis Obliterante/etiología , Femenino , Estudios de Seguimiento , Rechazo de Injerto/tratamiento farmacológico , Rechazo de Injerto/etiología , Supervivencia de Injerto , Humanos , Inmunosupresores/uso terapéutico , Quimioterapia de Inducción , Enfermedades Pulmonares/cirugía , Masculino , Persona de Mediana Edad , Complicaciones Posoperatorias , Pronóstico , Factores de Riesgo , Síndrome
4.
Appl Radiat Isot ; 67(7-8 Suppl): S63-6, 2009 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-19427224

RESUMEN

Local recurrence breast cancer is one of the most difficult conditions to cure and there is a need for new therapy. If sufficient boron compound can be targeted to the tumor, boron neutron capture therapy (BNCT) can be applied to local recurrent breast cancer. In this study, we performed a preliminary dosimetry with a phantom model of the mammary gland at Kyoto University Research Reactor (KUR), and a feasibility dosimetry with JAERI Computational Dosimetry System (JCDS) at JRR4 reactor of Japan Atomic Research Institute. We performed preliminary dosimetry of a phantom model of the mammary gland with thermal neutron irradiation (OO-0011 mode) on LiF collimation at KUR. The thermal neutron flux was 5.16 E+08 cm(-2)s(-1) at the surface of phantom. The blood boron concentration is estimated to be 30 ppm; tumor boron concentration is also estimated to be 90 ppm according to tumor/blood ratio 3 and skin/blood ratio 1.2. Tumor RBE dose is estimated to be 47 Gy/h, and skin RBE dose is 12.4 Gy/h. In case of advanced breast cancer, we performed the feasibility estimation of 3D construction of tumor according to the MRI imaging of a patient with epithermal neutron mode at JRR4. The blood boron concentration (ppm) and tumor/normal tissue ratio are estimated to be 24 and 3.5, respectively. Skin RBE dose is restricted to 10 Gy/h, the maximum tumor RBE dose, minimum tumor RBE dose, and mean tumor RBE dose are 42.2, 11.3, and 28.9 Gy-Eq, respectively, in half hour irradiation. In this study, we showed the possibility to apply BNCT to local recurrent breast cancer. We can irradiate tumors selectively and as safely as possible, reducing the effects on neighboring healthy tissues.


Asunto(s)
Terapia por Captura de Neutrón de Boro/métodos , Neoplasias de la Mama/radioterapia , Recurrencia Local de Neoplasia/radioterapia , Planificación de la Radioterapia Asistida por Computador/métodos , Terapia por Captura de Neutrón de Boro/estadística & datos numéricos , Neoplasias de la Mama/patología , Femenino , Humanos , Imagen por Resonancia Magnética , Recurrencia Local de Neoplasia/patología , Fantasmas de Imagen , Planificación de la Radioterapia Asistida por Computador/estadística & datos numéricos , Programas Informáticos
6.
Biomed Pharmacother ; 60(1): 43-50, 2006 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-16260113

RESUMEN

Tumour cell destruction in boron neutron-capture therapy (BNCT) is due to the nuclear reaction between (10)B and thermal neutrons. It is necessary for effective BNCT therapy to accumulate (10)B atoms in the tumour cells. The delivery system consisted of polyethylene-glycol (PEG) binding liposomes (DPPC/cholesterol/DSPC-PEG2000) with an entrapped (10)B-compound and we evaluated the cytotoxic effects of intravenously injected (10)B-PEG-liposomes on human pancreatic carcinoma xenografts in nude mice with thermal neutron irradiation. After thermal neutron irradiation of mice injected with (10)B-PEG-liposomes, growth of AsPC-1 tumours was suppressed relative to controls. Injection of (10)B-PEG-liposomes caused the greatest tumour suppression with thermal neutron irradiation in vivo. These results suggest that intravenous injection of (10)B-PEG-liposomes can increase the retention of (10)B atoms by tumour cells, causing suppression of tumour growth in vivo, after thermal neutron irradiation.


Asunto(s)
Borohidruros/administración & dosificación , Terapia por Captura de Neutrón de Boro , Boro/administración & dosificación , Neoplasias Pancreáticas/radioterapia , Compuestos de Sulfhidrilo/administración & dosificación , Animales , Línea Celular Tumoral , Humanos , Isótopos , Liposomas , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Modelos Animales , Trasplante de Neoplasias , Neoplasias Pancreáticas/metabolismo , Neoplasias Pancreáticas/patología , Polietilenglicoles/química
7.
Oral Oncol ; 40(3): 314-20, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-14747063

RESUMEN

The aim of this study was to analyze the iodine-unstained region expanding around oral squamous cell carcinoma (SCC) by quantification of telomerase activity. The epithelial dysplasia often observed around SCC is considered to cause local recurrence or a second primary cancer. However these areas are hard to distinguish from normal mucosa. To clear the border of the expanding epithelial dysplasia around SCC, we stained with 3% iodine solution, and then decided the surgical margin. We measured quantification of telomerase activity in tumor, in epithelial dysplasia, and also in normal epithelium. Thirty-three primary cases of oral SCC which have iodine-unstained region around lesions were investigated. Fluorescense-based TRAP was applied to obtain quantification of telomerase activity. We obtained the following results: histological examination confirmed that every patient's unstained region consisted of various degrees of epithelial dysplasia. The quantified telomerase activities for squamous cell carcinoma, epithelial dysplasia and normal epithelium were 53.9, 39.6 and 2.7 U/microgP, respectively, and there was a significant difference between carcinoma and normal areas, and between dysplasia and normal epithelium. Therefore, these findings suggest that the areas of epithelial dysplasia unstained by iodine consist of cells that are nearly cancerous and excessively proliferative, and that epithelial dysplasia around SCC should be resected together with the tumor. Vital staining with iodine is useful for identifying epithelial dysplasia around SCC.


Asunto(s)
Biomarcadores de Tumor/análisis , Carcinoma de Células Escamosas/enzimología , Neoplasias de la Boca/enzimología , Lesiones Precancerosas/enzimología , Telomerasa/análisis , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/patología , Epitelio/enzimología , Epitelio/patología , Femenino , Humanos , Yodo , Masculino , Persona de Mediana Edad , Mucosa Bucal/enzimología , Mucosa Bucal/patología , Neoplasias de la Boca/patología , Lesiones Precancerosas/patología , Coloración y Etiquetado
8.
Arch Androl ; 50(1): 11-4, 2004.
Artículo en Inglés | MEDLINE | ID: mdl-14660164

RESUMEN

Twenty-two idiopathic infertile patients were treated with Oriental herbal medicine, Bu-zhong-yi-qi-tang (Hochu-ekki-to). Seminal plasma sFas level elevated significantly after herb administration. There was an inverse correlation between seminal plasma IL-6 level and sperm concentration before treatment. After the administration of herb seminal plasma, sFas levels significantly correlated with sperm concentration. Seminal plasma IL-8 level did not change. Certain kinds of cytokine in the seminal plasma might play some role in improving semen quality with treatment.


Asunto(s)
Medicamentos Herbarios Chinos/uso terapéutico , Interleucina-6/metabolismo , Oligospermia/tratamiento farmacológico , Semen/metabolismo , Adulto , Humanos , Interleucina-8/metabolismo , Masculino , Semen/efectos de los fármacos , Semen/inmunología , Recuento de Espermatozoides , Motilidad Espermática/efectos de los fármacos , Receptor fas/metabolismo
9.
Arch Androl ; 49(6): 449-52, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14555327

RESUMEN

The seminal plasma levels of soluble Fas (sFas) and interleukins IL-6 and IL-8 were measured and their relationship with semen qualities was examined. The seminal plasma sFas level in fertile males was significantly higher than that in the infertile group. On the other hand, seminal plasma level of IL-6 was significantly lower in fertile males than in the infertile group. In the infertile group, patients with oligozoospermia had a lower seminal plasma sFas and a higher IL-6 level than those with normal sperm concentration. There was an inverse correlation between IL-6 and sperm concentration in infertile patients. Seminal plasma IL-8 was not correlated with sperm parameters. It would appear that certain kinds of cytokine in the seminal plasma might play an important role in improving semen quality.


Asunto(s)
Interleucina-8/metabolismo , Oligospermia/metabolismo , Semen/metabolismo , Receptor fas/metabolismo , Adulto , Humanos , Interleucina-6/metabolismo , Masculino , Persona de Mediana Edad , Oligospermia/patología , Motilidad Espermática , Espermatozoides/citología , Espermatozoides/fisiología
10.
Arch Androl ; 49(6): 479-82, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-14555334

RESUMEN

Laparoscopy revealed a left inguinal testis and a right abdominal testis. Surgery revealed uterus-like structures. The bilateral testes showed primitive testis without ovarian tissue. Physical examination showed a normal and an empty scrotum with a nonpalpable gonad. Chromosome analysis revealed 46,XY. Pathological findings demonstrated the immature testis and the immature uterus.


Asunto(s)
Criptorquidismo/cirugía , Trastornos del Desarrollo Sexual/cirugía , Conductos Paramesonéfricos/anomalías , Conductos Paramesonéfricos/cirugía , Procedimientos Quirúrgicos Urológicos Masculinos , Humanos , Lactante , Laparoscopía , Masculino , Síndrome , Resultado del Tratamiento
11.
Int Urol Nephrol ; 35(2): 189-92, 2003.
Artículo en Inglés | MEDLINE | ID: mdl-15072491

RESUMEN

The clinical and pathological features of metastatic prostate cancer with normal level of serum prostate-specific antigen (PSA) were investigated. Four patients with metastatic prostate cancer had serum PSA within the normal range at the diagnosis. All tumors were poorly-differentiated adenocarcinoma. Endocrine therapy was performed as the initial therapy in all patients. Despite subsequently treatment, all cases died of prostate cancer at 2, 8, 9 and 38 months. During disease progression, 3 of 4 patients had elevated serum markers such as carcinoembryonic antigen (CEA), CA19-9, CA15-3, CA125, neuron-specific enolase and pro-gastrin releasing peptide. Immunohistochemical examination of the initial biopsy specimens revealed that 4 and 3 cases were positive for CEA and chromogranin A, respectively. In advanced prostate cancer patients with low PSA level, those markers may aid in the follow up of disease.


Asunto(s)
Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Neoplasias de la Próstata/patología , Anciano , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Valores de Referencia
12.
Prostate Cancer Prostatic Dis ; 5(2): 159-63, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12497007

RESUMEN

Several prognostic factors such as the extent of bone metastases (EOD) in advanced prostate cancer (PCa) have been reported. Metastasis of the lung is rarely a significant clinical factor in the management of prostate cancer. The present study evaluates the clinical significance of lung metastases. We retrospectively reviewed the PCa database to identify patients with pulmonary metastases at initial diagnosis. The medical records of the patients were examined with respect to age, histologic grade, EOD score, marker response to endocrine therapy and clinical outcome. We then compared several potential clinical factors between patients with and without pulmonary metastases. Next, we retrospectively reviewed autopsy records of 60 Japanese patients who died of hormone-refractory metastatic PCa with particular focus upon metastatic profiles. A comparative study of stage D(2) patients with (n=20) and without (n=77) pulmonary metastases found no significant differences in EOD score, performance status, marker response and survival. Only tumor grade was better in the group with, than without pulmonary metastases (P=0.0120, chi-square analysis). In the series of autopsies, we found pulmonary metastases in 38 cases (63%), following metastases of the bone (57 cases, 95%) and lymph nodes (52 cases, 87%). A retrospective analysis of survival showed that patients with bone or lymph node metastases had a positive relative risk. In contrast, lung metastasis could be a positive prognostic indicator, although the findings were not statistically significant. These data suggest that the presence of pulmonary metastasis has no ominous impact on clinical course and disease outcome even in patients with disseminated prostate cancer.


Asunto(s)
Neoplasias Pulmonares/secundario , Estadificación de Neoplasias , Neoplasias de la Próstata/patología , Anciano , Anciano de 80 o más Años , Antineoplásicos Hormonales/farmacología , Antineoplásicos Hormonales/uso terapéutico , Autopsia , Neoplasias de la Médula Ósea/secundario , Bases de Datos Factuales , Resistencia a Antineoplásicos , Humanos , Metástasis Linfática , Masculino , Persona de Mediana Edad , Pronóstico , Neoplasias de la Próstata/tratamiento farmacológico , Sobrevida
13.
Int Urol Nephrol ; 33(1): 73-6, 2002.
Artículo en Inglés | MEDLINE | ID: mdl-12090344

RESUMEN

In order to examine the characteristics of patients with nonpalpable prostate cancer (T1c cancer) in Japan, patients treated with radical prostatectomy were compared with those with palpable (T2) cancer. Prostate-specific antigen (PSA) level in patients with T2b disease was significantly higher than those with T1c and T2a tumors. At the time of radical prostatectomy, 78%, 71% and 31% of patients with T1c, T2a, and T2b, respectively, had organ-confined disease. When insignificant cancer was defined as volume 0.5 ml or less and Gleason score less than 5, only 2 of 34 (5.9%) with clinical T1c disease were clinically insignificant. T1c cancers were clinically significant and clinicopathological features of Tlc tumors were similar to T2a tumors. PSA measurement could detect potentially curable prostate cancer.


Asunto(s)
Adenocarcinoma/patología , Adenocarcinoma/cirugía , Antígeno Prostático Específico/análisis , Prostatectomía/métodos , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Adenocarcinoma/mortalidad , Anciano , Análisis de Varianza , Biomarcadores de Tumor/análisis , Biopsia con Aguja , Estudios de Cohortes , Humanos , Inmunohistoquímica , Japón , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Palpación , Probabilidad , Pronóstico , Neoplasias de la Próstata/mortalidad , Muestreo , Sensibilidad y Especificidad , Análisis de Supervivencia
14.
Biomed Pharmacother ; 56(2): 93-9, 2002 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-12000141

RESUMEN

Cell destruction in boron neutron capture therapy is effected by nuclear reaction between 10B and thermal neutrons with the release of alpha-particles (4He) and lithium-7 ions (7Li). 4He kills cells within 10 microm of the site of 4He generation, therefore it is theoretically possible to destroy tumour cells without affecting adjacent healthy tissue, given selective delivery of compounds containing 10B. Liposomes wore prepared by vortex dispersion of solutions containing 10B compounds with dried lipid films and the effects of those compounds on human breast cancer cells in culture were examined after thermal neutral irradiation. [3H]-TdR incorporation by MRKnu/nu-1 cells treated with 10B-containing liposomes showed 40% suppression compared with liposomes without 10B, at 2 x 1012 n/cm2 thermal neutron fluence. Inhibition of tumour cell growth with liposomes prepared with 100 mm 10B-compound was as significant as with those made with 500 ppm 10B solution. The concentration of 10B in liposomes was 76.5 +/- 3.4 microg/mL. Boronated liposomes can thus deliver sufficient 10B atoms to this line of breast cancer cells in culture to effect cytotoxicity and suppression of growth after thermal neutron irradiation.


Asunto(s)
Terapia por Captura de Neutrón de Boro/métodos , Boro/administración & dosificación , Boro/uso terapéutico , Neoplasias de la Mama/patología , Neoplasias de la Mama/radioterapia , Liposomas/administración & dosificación , División Celular , Rayos gamma , Humanos , Isótopos/administración & dosificación , Isótopos/uso terapéutico , Liposomas/química , Neutrones , Soluciones , Células Tumorales Cultivadas
16.
Biol Pharm Bull ; 24(6): 600-6, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11411544

RESUMEN

We have reported fatty alcohol synthesis accompanied by chain elongation in liver peroxisomes (Biochim. Biophys. Acta, 1346, 38 (1997)). In the present experiment, we studied what kind of acyl-CoA(s) destined to be utilized as primer for fatty alcohol synthesis accumulate(s) during peroxisomal beta-oxidation. Peroxisomes were prepared from rat liver treated with clofibrate, a peroxisome proliferator, and incubated with [U-14C]palmitate, in order to investigate acyl-CoAs after beta-oxidation. At 1 mM concentration, MgATP activated beta-oxidation, but inhibited beta-oxidation at concentrations higher than 1 mM. After incubation of peroxisomes with palmitate, various acyl-CoAs were formed. Among medium-chain labelled acyl-CoAs, octanoyl-CoA was mainly detected. These results suggest that octanoyl-CoA accumulates during beta-oxidation of palmitate. When peroxisomes were incubated with [9,10-(3)H]palmitate and [9,10-(3)H]stearate, among medium-chain acyl-CoAs, octanoyl-CoA and decanoyl-CoA were primarily detected, respectively, suggesting the occurrence of at least 4 cycles of beta-oxidation of both fatty acids by peroxisomes.


Asunto(s)
Acilcoenzima A/metabolismo , Hígado/ultraestructura , Peroxisomas/metabolismo , Adenosina Trifosfato/farmacología , Animales , Cromatografía Líquida de Alta Presión , Clofibrato/administración & dosificación , Ésteres , Masculino , Oxidación-Reducción , Ácido Palmítico/metabolismo , Peroxisomas/efectos de los fármacos , Ratas , Ratas Wistar , Ácidos Esteáricos/metabolismo
17.
Anticancer Res ; 21(2B): 1317-20, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11396206

RESUMEN

The prostate-specific antigen (PSA) density of the transition zone (PSATZ) in 45 prostate cancer patients who received radical prostatectomy with a PSA value of 4.1-10 ng/ml was determined to see whether PSATZ was useful in the prediction of extracapsular invasion of prostate cancer. The value of PSATZ for the detection of extracapsular invasion was compared with that of PSA and PSA density (PSAD). Thirty-one patients (68.9%) had pathologically organ confined cancer while 14 (31.1%) had extracapsular disease. Patients with organ confined tumor had significantly lower PSAD and PSATZ than those with non-organ confined tumor. PSATZ was superior to PSA when analyzed by receiver operating characteristics curves. In those patients with a cut-off value of 1.0 ng/ml per ml of transition zone volume, the PSATZ had a sensitivity of 43% and a specificity of 90% for prediction of extracapsular extension. The present study demonstrated that PSATZ was superior to PSA as a predictor of extracapsular invasion in intermediate PSA levels. Measurement of PSATZ may be of additional value to indicate the need for radical prostatectomy.


Asunto(s)
Adenocarcinoma/sangre , Antígeno Prostático Específico/sangre , Neoplasias de la Próstata/sangre , Adenocarcinoma/fisiopatología , Adenocarcinoma/cirugía , Humanos , Japón , Masculino , Invasividad Neoplásica , Estadificación de Neoplasias , Valor Predictivo de las Pruebas , Neoplasias de la Próstata/fisiopatología , Neoplasias de la Próstata/cirugía
18.
Int J Urol ; 8(5): 222-6, 2001 May.
Artículo en Inglés | MEDLINE | ID: mdl-11328422

RESUMEN

BACKGROUND: Long-term results were analyzed to evaluate the role of endocrine therapy in the management of local and distant recurrence of prostate cancer following external radiation therapy. METHODS: Between 1976 and 1994, 92 patients with untreated prostate cancer underwent external beam radiation therapy alone. Endocrine therapy had been started when relapse was evident. RESULTS: Failure was seen in 35 of 92 patients: 10 local, 19 distant and six biochemical failures. Endocrine treatment was performed in 28 patients with nine local and 19 distant failures. The cancer-specific survival rate from the endocrine treatment was 54.5% at 5 years. Prostate-specific antigen level in 20 of 20 patients (100%) decreased to below the normal limit 3 months after the start of endocrine therapy. In univariate analysis, T classification was the most significant variable for cancer-specific survival from the initial treatment. CONCLUSIONS: A favorable outcome was achieved by endocrine therapy in patients who had relapsed after external beam radiation monotherapy. Even the recurrent tumor had a sensitivity to androgen. Patients with locally advanced disease (T2b and T3) had poorer prognosis than those with minimally extended disease (T1b and T2a).


Asunto(s)
Recurrencia Local de Neoplasia/terapia , Neoplasias de la Próstata/terapia , Anciano , Anciano de 80 o más Años , Antagonistas de Andrógenos/uso terapéutico , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Orquiectomía , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/radioterapia
19.
J Vet Med Sci ; 63(2): 125-33, 2001 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-11258447

RESUMEN

Extracellular matrix components (ECMs) in histological sections of the kidney cortex from the rats with adriamycin (ADR)-induced nephropathy (5 mg/kg, i.v.) were quantified by an immunohistochemical micromethod. Changes in kidney histopathology and urine and blood biochemistry were investigated. Enlarged kidneys were granular on the surface and pale in color in ADR-treated rats, and these rats had kidneys with glomeruli with expanded mesangial area and with capillary aneurysm. Severe albuminuria, hypoalbuminemia, hypercholesterolemia and disorders in other nephrotic parameters were observed in ADR-treated rats. Type I and IV collagens, fibronectin and laminin contents in the renal cortex of ADR-treated rats at 10 weeks were 329, 317, 263 and 295%, respectively, higher than in each vehicle control, and those at 28 weeks were 1,211, 930, 1,057 and 1,012%, respectively. The glomerular sclerotic abnormalities progressed in a time-dependent manner. Moreover, there was a strong correlation between the ECM levels and serum creatinine and blood urea nitrogen levels. In conclusion, microquantification provided useful information for accurate diagnosis and prognosis of nephrotic lesions and is a good tool to assess the advancement of renal disorders in patients with nephropathy.


Asunto(s)
Antibióticos Antineoplásicos/toxicidad , Doxorrubicina/toxicidad , Matriz Extracelular/metabolismo , Glomeruloesclerosis Focal y Segmentaria/veterinaria , Enfermedades de los Roedores/patología , Albuminuria/orina , Animales , Nitrógeno de la Urea Sanguínea , Colesterol/sangre , Colágeno/metabolismo , Creatinina/sangre , Fibronectinas/metabolismo , Glomeruloesclerosis Focal y Segmentaria/inducido químicamente , Glomeruloesclerosis Focal y Segmentaria/patología , Inmunohistoquímica/veterinaria , Laminina/metabolismo , Masculino , Ratas , Ratas Endogámicas Lew , Enfermedades de los Roedores/inducido químicamente , Albúmina Sérica/análisis , Estadísticas no Paramétricas
20.
Jpn J Clin Oncol ; 31(1): 13-7, 2001 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-11256835

RESUMEN

BACKGROUND: Estimation of survival probability of individual patients with metastatic renal cell carcinoma was difficult owing to diverse prognostic factors. We analyzed serum immunosuppressive acidic protein (IAP) levels and the cutoff value, then tested its validity for assessing patients' prognoses. METHODS: Serum IAP was measured longitudinally in 84 patients with metastatic disease. Before therapy, cutoff levels of IAP were tested every 20 microg/ml between 600 and 1200 microg/ml. The prognostic importance of IAP and its cutoff level was estimated. RESULTS: The cutoff level of IAP was set at 800 microg/ml for 40 patients who had metastatic disease with the primary tumor in situ and for 44 patients with recurrent disease. IAP was found to be a significant prognostic factor for both patient groups. CONCLUSIONS: Serum IAP is an important prognostic factor for patients with metastatic renal cell carcinoma. Stratification of patients according to prognosis is feasible using the cutoff level.


Asunto(s)
Biomarcadores de Tumor/sangre , Carcinoma de Células Renales/sangre , Neoplasias Renales/sangre , Proteínas de Neoplasias/sangre , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Renales/patología , Femenino , Humanos , Neoplasias Renales/patología , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Metástasis de la Neoplasia , Pronóstico , Reproducibilidad de los Resultados , Tasa de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA